Matches in SemOpenAlex for { <https://semopenalex.org/work/W3162626225> ?p ?o ?g. }
- W3162626225 endingPage "401" @default.
- W3162626225 startingPage "388" @default.
- W3162626225 abstract "The PML/RARα fusion protein is the oncogenic driver in acute promyelocytic leukemia (APL). Although most APL cases are cured by PML/RARα-targeting therapy, relapse and resistance can occur due to drug-resistant mutations. Here we report that thermal stress destabilizes the PML/RARα protein, including clinically identified drug-resistant mutants. AML1/ETO and TEL/AML1 oncofusions show similar heat shock susceptibility. Mechanistically, mild hyperthermia stimulates aggregation of PML/RARα in complex with nuclear receptor corepressors leading to ubiquitin-mediated degradation via the SIAH2 E3 ligase. Hyperthermia and arsenic therapy destabilize PML/RARα via distinct mechanisms and are synergistic in primary patient samples and in vivo, including three refractory APL cases. Collectively, our results suggest that by taking advantage of a biophysical vulnerability of PML/RARα, thermal therapy may improve prognosis in drug-resistant or otherwise refractory APL. These findings serve as a paradigm for therapeutic targeting of fusion oncoprotein-associated cancers by hyperthermia.Hyperthermia destabilizes oncofusion proteins including PML/RARα and acts synergistically with standard arsenic therapy in relapsed and refractory APL. The results open up the possibility that heat shock sensitivity may be an easily targetable vulnerability of oncofusion-driven cancers.See related commentary by Wu et al., p. 300." @default.
- W3162626225 created "2021-05-24" @default.
- W3162626225 creator A5000239300 @default.
- W3162626225 creator A5001717980 @default.
- W3162626225 creator A5007795273 @default.
- W3162626225 creator A5009811034 @default.
- W3162626225 creator A5015235822 @default.
- W3162626225 creator A5017193282 @default.
- W3162626225 creator A5018767367 @default.
- W3162626225 creator A5019573704 @default.
- W3162626225 creator A5021213254 @default.
- W3162626225 creator A5021888505 @default.
- W3162626225 creator A5022499603 @default.
- W3162626225 creator A5024735033 @default.
- W3162626225 creator A5024789842 @default.
- W3162626225 creator A5029438350 @default.
- W3162626225 creator A5038243976 @default.
- W3162626225 creator A5039925860 @default.
- W3162626225 creator A5044554947 @default.
- W3162626225 creator A5045149653 @default.
- W3162626225 creator A5047465008 @default.
- W3162626225 creator A5049370838 @default.
- W3162626225 creator A5055273232 @default.
- W3162626225 creator A5060013309 @default.
- W3162626225 creator A5063046732 @default.
- W3162626225 creator A5063250623 @default.
- W3162626225 creator A5063473974 @default.
- W3162626225 creator A5063622346 @default.
- W3162626225 creator A5065898323 @default.
- W3162626225 creator A5066306425 @default.
- W3162626225 creator A5066644948 @default.
- W3162626225 creator A5067295487 @default.
- W3162626225 creator A5068511869 @default.
- W3162626225 creator A5069897350 @default.
- W3162626225 creator A5076559212 @default.
- W3162626225 creator A5078812361 @default.
- W3162626225 creator A5081079627 @default.
- W3162626225 creator A5085889761 @default.
- W3162626225 creator A5086445887 @default.
- W3162626225 creator A5087650967 @default.
- W3162626225 creator A5087902006 @default.
- W3162626225 date "2021-05-11" @default.
- W3162626225 modified "2023-10-18" @default.
- W3162626225 title "Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins" @default.
- W3162626225 cites W1486948598 @default.
- W3162626225 cites W1977709885 @default.
- W3162626225 cites W1981217436 @default.
- W3162626225 cites W2009278076 @default.
- W3162626225 cites W2017653822 @default.
- W3162626225 cites W2030248691 @default.
- W3162626225 cites W2033177440 @default.
- W3162626225 cites W2037200527 @default.
- W3162626225 cites W2037310970 @default.
- W3162626225 cites W2039003881 @default.
- W3162626225 cites W2042337609 @default.
- W3162626225 cites W2044229112 @default.
- W3162626225 cites W2048306488 @default.
- W3162626225 cites W2073651235 @default.
- W3162626225 cites W2107715878 @default.
- W3162626225 cites W2131321938 @default.
- W3162626225 cites W2132981855 @default.
- W3162626225 cites W2139472488 @default.
- W3162626225 cites W2155548073 @default.
- W3162626225 cites W2156124327 @default.
- W3162626225 cites W2158958901 @default.
- W3162626225 cites W2162278279 @default.
- W3162626225 cites W2162919209 @default.
- W3162626225 cites W2163954540 @default.
- W3162626225 cites W2170325085 @default.
- W3162626225 cites W2178127438 @default.
- W3162626225 cites W2473711714 @default.
- W3162626225 cites W2681714461 @default.
- W3162626225 cites W2768202893 @default.
- W3162626225 cites W2806637980 @default.
- W3162626225 cites W2889261354 @default.
- W3162626225 cites W2909350868 @default.
- W3162626225 cites W2910571066 @default.
- W3162626225 cites W2984236321 @default.
- W3162626225 cites W3117264612 @default.
- W3162626225 cites W3135051742 @default.
- W3162626225 doi "https://doi.org/10.1158/2643-3230.bcd-20-0188" @default.
- W3162626225 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8513904" @default.
- W3162626225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34661159" @default.
- W3162626225 hasPublicationYear "2021" @default.
- W3162626225 type Work @default.
- W3162626225 sameAs 3162626225 @default.
- W3162626225 citedByCount "25" @default.
- W3162626225 countsByYear W31626262252021 @default.
- W3162626225 countsByYear W31626262252022 @default.
- W3162626225 countsByYear W31626262252023 @default.
- W3162626225 crossrefType "journal-article" @default.
- W3162626225 hasAuthorship W3162626225A5000239300 @default.
- W3162626225 hasAuthorship W3162626225A5001717980 @default.
- W3162626225 hasAuthorship W3162626225A5007795273 @default.
- W3162626225 hasAuthorship W3162626225A5009811034 @default.
- W3162626225 hasAuthorship W3162626225A5015235822 @default.
- W3162626225 hasAuthorship W3162626225A5017193282 @default.
- W3162626225 hasAuthorship W3162626225A5018767367 @default.